Evidence map›Paper›PMID 33240865›Full record

ArticleFrontiers in bioengineering and biotechnology2020

The StemCellFactory: A Modular System Integration for Automated Generation and Expansion of Human Induced Pluripotent Stem Cells.

Andreas Elanzew, Bastian Nießing, Daniel Langendoerfer, Oliver Rippel, Tobias Piotrowski, Friedrich Schenk, Michael Kulik, Michael Peitz, Yannik Breitkreuz, Sven Jung and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Advancements in theFrontiers in toxicology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Andreas ElanzewInstitute of Reconstructive Neurobiology, University of Bonn Medical Faculty and University Hospital Bonn, Bonn, Germany.
Bastian NießingFraunhofer Institute for Production Technology, Aachen, Germany.
Daniel LangendoerferLIFE&BRAIN GmbH, Cellomics Unit, Bonn, Germany.
Oliver RippelLIFE&BRAIN GmbH, Cellomics Unit, Bonn, Germany.
Tobias PiotrowskiFraunhofer Institute for Production Technology, Aachen, Germany.
Friedrich SchenkFraunhofer Institute for Production Technology, Aachen, Germany.
Michael KulikFraunhofer Institute for Production Technology, Aachen, Germany.
Michael PeitzInstitute of Reconstructive Neurobiology, University of Bonn Medical Faculty and University Hospital Bonn, Bonn, Germany.
Yannik BreitkreuzInstitute of Reconstructive Neurobiology, University of Bonn Medical Faculty and University Hospital Bonn, Bonn, Germany.
Sven JungFraunhofer Institute for Production Technology, Aachen, Germany.
Paul WanekInstitute for Biomedical Engineering, Cell Biology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Laura StappertLIFE&BRAIN GmbH, Cellomics Unit, Bonn, Germany.
Robert H SchmittFraunhofer Institute for Production Technology, Aachen, Germany.
Simone HauptInstitute of Reconstructive Neurobiology, University of Bonn Medical Faculty and University Hospital Bonn, Bonn, Germany.
Martin ZenkeInstitute for Biomedical Engineering, Cell Biology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Niels KönigFraunhofer Institute for Production Technology, Aachen, Germany.
Oliver BrüstleInstitute of Reconstructive Neurobiology, University of Bonn Medical Faculty and University Hospital Bonn, Bonn, Germany.
Fraunhofer Institute for Production Technology IPT · DELife & Brain (Germany) · DERWTH Aachen University · DEUniversity Hospital Bonn · DEUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While human induced pluripotent stem cells (hiPSCs) provide novel prospects for disease-modeling, the high phenotypic variability seen across different lines demands usage of large hiPSC cohorts to decipher the impact of individual genetic variants. Thus, a much higher grade of parallelization, and throughput in the production of hiPSCs is needed, which can only be achieved by implementing automated solutions for cell reprogramming, and hiPSC expansion. Here, we describe the StemCellFactory, an automated, modular platform covering the entire process of hiPSC production, ranging from adult human fibroblast expansion, Sendai virus-based reprogramming to automated isolation, and parallel expansion of hiPSC clones. We have developed a feeder-free, Sendai virus-mediated reprogramming protocol suitable for cell culture processing via a robotic liquid handling unit that delivers footprint-free hiPSCs within 3 weeks with state-of-the-art efficiencies. Evolving hiPSC colonies are automatically detected, harvested, and clonally propagated in 24-well plates. In order to ensure high fidelity performance, we have implemented a high-speed microscope for in-process quality control, and image-based confluence measurements for automated dilution ratio calculation. This confluence-based splitting approach enables parallel, and individual expansion of hiPSCs in 24-well plates or scale-up in 6-well plates across at least 10 passages. Automatically expanded hiPSCs exhibit normal growth characteristics, and show sustained expression of the pluripotency associated stem cell marker TRA-1-60 over at least 5 weeks (10 passages). Our set-up enables automated, user-independent expansion of hiPSCs under fully defined conditions, and could be exploited to generate a large number of hiPSC lines for disease modeling, and drug screening at industrial scale, and quality.

Indexed as

automationcell culturecell productioninduced pluripotent stem cellsreprogramming

Identifiers

PMID33240865
PMCPMC7680974
OpenAlexW3104460396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.